Drug maker Lupin Friday said it has received the US health regulator's approval to market a generic version of Sanofi Aventis' Rifadin capsules, used to treat tuberculosis, in the American market.
Lupin Pharmaceuticals Inc, the Mumbai-based firm's US-based subsidiary, has received final approval from US Food and Drug Administration (USFDA) for its Rifampin Capsules in 150 mg and 300 mg strengths, Lupin said in a statement.
Rifampin Capsules are indicated for the treatment of all forms of tuberculosis.
It is also prescribed for the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx.
As per the IMS sales data, Rifadin Capsules had annual US sales of around $18.5 million.
